Rare Multisystem Histiocytic Sarcoma on F-FDG PET/CT.

J Nucl Med Technol

Department of Radiology, Mayo Clinic Arizona, Scottsdale, Arizona; and

Published: December 2021

Histiocytic sarcoma (HS) is a rare malignancy with morphologic and immunophenotypic features indicating histiocytic differentiation. We present a case of HS with multisystem involvement, including an obstructing mass in the pancreatic head. F-FDG PET/CT is a valuable tool in staging this rare entity and in assessing the response to therapy. Knowing the diverse metastatic pattern of HS will help avoid imaging pitfalls on clinical F-FDG PET/CT scans.

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnmt.121.262247DOI Listing

Publication Analysis

Top Keywords

f-fdg pet/ct
12
histiocytic sarcoma
8
rare multisystem
4
multisystem histiocytic
4
sarcoma f-fdg
4
pet/ct histiocytic
4
sarcoma rare
4
rare malignancy
4
malignancy morphologic
4
morphologic immunophenotypic
4

Similar Publications

Background/objectives: The purpose of this study was to develop the gemcitabine-loaded drug-eluting beads (G-DEBs) for transarterial chemoembolization (TACE) in rabbit renal tumors and to evaluate their antitumor effect using 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/X-ray computed tomography (F-FDG PET/CT).

Methods: DEBs were prepared by polyvinyl alcohol-based macromer crosslinked with -acryl tyrosine and ,'-methylenebis(acrylamide). Gemcitabine was loaded through ion change to obtain G-DEBs.

View Article and Find Full Text PDF

Non-[F]FDG PET-Radiopharmaceuticals in Oncology.

Pharmaceuticals (Basel)

December 2024

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Molecular imaging is a growing field, driven by technological advances, such as the improvement of PET-CT scanners through the introduction of digital detectors and scanners with an extended field of view, resulting in much higher sensitivity and a variety of new specific radiopharmaceuticals that allow the visualization of specific molecular pathways and even theragnostic approaches. In oncology, the development of dedicated tracers is crucial for personalized therapeutic approaches. Novel peptides allow the visualization of many different targets, such as PD-1 and PD-L1 expression, chemokine expression, HER expression, T-cell imaging, microenvironmental imaging, such as FAP imaging, and many more.

View Article and Find Full Text PDF

Cutaneous malignant melanoma (MM) is the most aggressive form of skin cancer, associated with high mortality and rising incidence rates in Europe despite prevention efforts. Nodular MM, the most aggressive subtype, often mimics other skin tumors, complicating diagnosis. We present the case of a 66-year-old woman with a large, ulcerated tumor beneath the left scapula, along with multiple nodular lesions on the left arm and chest.

View Article and Find Full Text PDF

Ductal carcinoma (DCIS), a noninvasive breast cancer, rarely metastasises to distant locations. When the initial lesion is stable, bone marrow metastasis (BMM) and bone marrow necrosis (BMN) are even less common. Here, we report the case of a 47-year-old female patient who underwent localized surgery and radiotherapy for right-sided DCIS.

View Article and Find Full Text PDF

Fibroblast activation protein (FAPI) has been recently incorporated as a molecular imaging radiotracer for the evaluation of epithelial neoplasms that support or complement the role of [F]Fluorodeoxyglucose ([F]FDG) in many cancer subtypes since its development. Both radiotracers have been shown to have diagnostic, prognostic, and predictive value for several neoplasms. Herein, we present a 73-year-old male patient with a complex medical and oncological history who was recently diagnosed with hepatocellular carcinoma (HCC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!